Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

• Published in: Cellular and molecular gastroenterology and hepatology 2020-01, Vol.10 (4), p.829-851
• Main Authors: Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.
• Format: Article
• Language: English
• Subjects: Acetyl-CoA Carboxylase; Acetyl-CoA Carboxylase - antagonists & inhibitors; Acetyl-CoA Carboxylase - metabolism; Animals; Enzyme Inhibitors - therapeutic use; Fatty Liver Disease; Fibrosis; Humans; Lipogenesis; Lipogenesis - drug effects; Liver - drug effects; Liver - metabolism; Liver - pathology; Male; NASH; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Original Research; Rats, Sprague-Dawley
• ISSN: 2352-345X; 2352-345X
• DOI: 10.1016/j.jcmgh.2020.06.001

Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis (DNL) and modulates mitochondrial fatty acid oxidation. Increased hepatic DNL flux and reduced fatty acid oxidation are hypothesized to contribute to steatosis. Some proinflammatory cells also show increased dependency on DNL, suggesting that ACC may regulate aspects of the inflammatory response in NASH. PF-05221304 is an orally bioavailable, liver-directed ACC1/2 inhibitor. The present studies sought to evaluate the effects of PF-05221304 on NASH pathogenic factors in experimental model systems. The effects of PF-05221304 on lipid metabolism, steatosis, inflammation, and fibrogenesis were investigated in both primary human-derived in vitro systems and in vivo rodent models. PF-05221304 inhibited DNL, stimulated fatty acid oxidation, and reduced triglyceride accumulation in primary human hepatocytes, and reduced DNL and steatosis in Western diet–fed rats in vivo, showing the potential to reduce hepatic lipid accumulation and potentially lipotoxicity. PF-05221304 blocked polarization of human T cells to proinflammatory but not anti-inflammatory T cells, and suppressed activation of primary human stellate cells to myofibroblasts in vitro, showing direct effects on inflammation and fibrogenesis. Consistent with these observations, PF-05221304 also reduced markers of inflammation and fibrosis in the diethylnitrosamine chemical–induced liver injury model and the choline-deficient, high-fat–fed rat model. The liver-directed dual ACC1/ACC2 inhibitor directly improved multiple nonalcoholic fatty liver disease/NASH pathogenic factors including steatosis, inflammation, and fibrosis in both human-derived in vitro systems and rat models. [Display omitted]